Method for capturing and releasing circulating tumor cells based on phage magnetic material

By combining the multivalent display of M13 phage magnetic material with DNase I enzyme, the problem of low efficiency in capturing and releasing circulating tumor cells in traditional methods is solved, achieving highly efficient CTC capture and release, which is suitable for the diagnosis and subtype differentiation of breast cancer samples.

CN119020287APending Publication Date: 2024-11-26NORTHEASTERN UNIV CHINA
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202310603937.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing technologies suffer from low efficiency and low purity when capturing and releasing circulating tumor cells. In particular, the EpCAM antibody-modified magnetic bead method is ineffective when EpCAM expression decreases, and the spatial crowding effect of traditional aptamer materials affects capture and release performance.

Method used

Using M13 phage magnetic material, the binding of the MUC1 aptamer and DNase I enzyme is demonstrated through the multivalent display of pVIII protein, enabling the capture and release of EpCAM negative cells. The flexibility of M13 phage is utilized to enhance multivalent interactions, and magnetic beads are connected via click reaction to improve capture and release efficiency.

Benefits of technology

The capture efficiency in whole blood was increased by 46.4%, the release efficiency was increased by 35%, the false negative rate and false negative results were reduced, and the differentiation of different breast cancer subtypes and efficient CTC diagnosis were achieved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020287A_ABST
    Figure CN119020287A_ABST
Patent Text Reader

Abstract

A method for capturing and releasing circulating tumor cells based on a phage magnetic material belongs to the technical field of biological materials, and adopts an M13 phage as a support, pIII protein gene display histidine is connected with a magnetic sphere, and pVIII protein modifies an MUC1 aptamer through a click reaction for capturing and releasing the circulating tumor cells. The capture efficiency of the prepared M13 phage magnetic material on CTC reaches 95.63%, the release efficiency is 89.98%, and the cell activity reaches 97.14%. Compared with a traditional method for direct modification by using a monovalent aptamer, the capture efficiency of the system in whole blood is improved by 46.4%, and the release efficiency is improved by 35%. The M13 bacteriophage magnetic material can also be used for diagnosing actual breast cancer samples and distinguishing subtypes of different breast cancers, also has good capture performance on EpCAM negative cells, and greatly reduces the omission ratio and false negative results of CTCs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomaterials, and in particular relates to a method for capturing and releasing circulating tumor cells based on bacteriophage magnetic materials. Background Art

[0002] Circulating tumor cells (CTCs) are tumor cells that are shed from primary tumor tissue into the blood circulation, causing the spread of tumors. They carry important information related to the diagnosis and treatment of cancer, and therefore can be used as an important marker for the early diagnosis of cancer. However, the number of CTCs in whole blood is extremely small. There are billions of red blood cells and millions of white blood cells in 1 mL of whole blood, but only a few to dozens of CTCs. At the same time, CTCs have strong heterogeneity in different tumors or different locations of the same tumor, which brings great difficulties to the platform for enriching CTCs for early cancer detection. Therefore, efficient enrichment, specific detection, and high-purity capture of CTCs are the key to early cancer diagnosis.

[0003] In recent years, antibody-coupled magnetic nanomaterials have been widely used to capture CTCs in whole blood. However, there are very few types of antibody molecules as cell markers, and the commonly used anti-epithelial cell adhesion molecule (EpCAM) antibodies are also limited by the heterogeneity of cells, which affects the recognition and enrichment of CTCs. As a new type of recognition molecule, nucleic acid aptamers have the advantages of high affinity with target molecules, small size, multiple recognition protein types and good stability, and have great potential as an alternative to antibody recognition ligands. Therefore, how to modify aptamers with appropriate methods to achieve efficient capture and release is a hot issue in the current research on circulating tumor cells.

[0004] Immunoisolation based on antigen-antibody specific binding is an effective method to achieve specific enrichment of CTCs in whole blood. Among them, magnetic beads modified with EpCAM antibodies have high repeatability in separating CTCs and are currently the only CTC detection technology certified by the US FDA. Unfortunately, due to the decrease in EpCAM expression on the cell surface of CTCs during the epithelial-mesenchymal process, the CTC enrichment efficiency and purity of this method are not high. Therefore, many people are committed to developing immune enrichment methods with higher capture efficiency, higher purity and higher sensitivity. For example, antigen-antibody immunoisolation methods based on microfluidic chip technology or preparation of nanostructured materials, etc. However, these methods require complex operations and designs, are time-consuming, have high work intensity, and require operators to have professional technical capabilities, etc. There is still a lot of room for improvement for wider application.

[0005] Traditional magnetic materials for aptamer-captured cells are based on aptamers directly attached to the material surface for capturing CTCs. However, disordered aptamers can only achieve specific monovalent recognition and capture of accessible CTC surfaces, which greatly affects the capture performance of CTCs. At the same time, the local spatial crowding effect of aptamers on the material surface hinders the accessibility of the target site of the released molecule, reduces the release efficiency of cells, and thus seriously affects the downstream analysis of CTCs. Therefore, a new type of CTC capture affinity material is urgently needed for efficient enrichment and release of CTCs. Summary of the invention

[0006] The purpose of the present invention is to provide a method for capturing and releasing circulating tumor cells based on bacteriophage magnetic materials, wherein the bacteriophage magnetic material is specifically an M13 bacteriophage magnetic material.

[0007] The purpose of the present invention is achieved by the following technical solutions:

[0008] M13 phage coupled with MUC1 aptamer can capture target cells even if EpCAM is negatively expressed. Based on the M13 phage magnetic material, it can achieve capture and differentiation of different subtypes in actual clinical breast cancer samples. Based on the characteristics of synergistic M13 phage pVIII protein multivalent display and flexible swing, 2700 pVIII protein copies provide enough reaction sites for hundreds of binding ligands. At the same time, the flexibility of M13 phage allows it to freely twist and adjust the ligand configuration and adapt to the distribution pattern of target receptors on the cell surface, thereby greatly enhancing its multivalent interaction with CTC. In addition, the swing of phage is more conducive to DNase I enzyme contact with aptamer to increase the release of CTC.

[0009] The present invention uses M13 phage as a scaffold, pIII protein phage displays histidine for connecting to nickel-modified magnetic spheres, and pVIII protein multivalently displays MUC1 aptamers (Apt) for capturing circulating tumor cells, and affinity release of captured cells is achieved by adding DNase I enzyme. The multivalent display and flexible swinging characteristics of M13 phage pVIII protein significantly enhance the multivalent capture and release performance of CTCs, while connecting to MUC1 aptamers to achieve specific capture of EpCAM negative cells and achieve typing of different breast cancer cells.

[0010] A method for preparing an M13 bacteriophage magnetic material, comprising the following steps:

[0011] Preparation of 6His-M13 phage: M13 phage displays 6His tag at the N-terminus of pill protein by inserting a short sequence encoding HHHHHH between two restriction sites of Acc65I and EagI in M13KE vector. Two synthetic phosphorylated oligonucleotide chains 6H-PSA1 (5'-GTACCTTTCTATTCTCACTCTCATCATCATCATCATCATTCCTCCAAACTGCAGTC-3) and 6H-PSA2 (5'-GGCCGACTGCAGTTTGGAGGAATGATGATGATGATGATGAGAGTGAGAATAGAAAG-3) were annealed and hybridized at 90-100℃ for 2-10min to obtain double-stranded DNA 6H-PSA at the end for ligation. M13KE vector was digested with Acc65I and EagI and purified with gel purification kit. 6H-PSA was ligated into linearized M13KE with T4 ligase at 4-20℃ overnight. The ligation product was transformed into chemically competent host cells using the CaCl2 transformation method. Phage plaques were screened on LB agar plates containing IPTG (isopropyl-β-D-thiogalactopyranoside) and X-Gal and verified by DNA sequencing.

[0012] Synthesis of N3-M13: Take 1-100 μL of the titer of 1×10 11 pfu / mL~8×10 13 pfu / mL of 6His-M13 phage was dissolved in 150-300 μL of 10-100 mM sterile PBS buffer solution (pH 7-8) and mixed, and 100-200 μL of 5-20 mM NHS-PEG-N3 solution was added, mixed evenly, and placed in a shaker at a temperature of 0-37°C for 10-24 hours. The solution after the reaction was taken out, and the excess NHS-PEG-N3 reagent was removed by ultrafiltration tube to obtain N3-M13, which was placed in a refrigerator at 0-15°C for use.

[0013] Preparation of M13-MB: Take 1-5 mg / mL IDA-MBs storage solution (referring to His-Tag protein purification magnetic beads (nickel ion) IDA-Nickel), wash three times with 5-20 mM PBST (pH 6-8, containing 0.05-5% BSA, 0.01-0.5% tween-20) buffer solution, and resuspend in PBST solution after magnetic separation. Add purified 1×10 9 pfu~1×10 12The pfu N3-M13 solution was evenly mixed and placed in a mixer for reaction for 30 min to 12 h. The product after the reaction was magnetically separated, washed twice with PBST buffer and resuspended to obtain M13-MB, which was placed in a refrigerator at 0 to 15°C for use.

[0014] Apt-M13-MB: MUC1 aptamer (5'-TTTTTGCAGTTGATCCTTTGGATACCCTGG-3', DBCO modified) was diluted with TE buffer solution (5-20 mM tris-HCl, 0.5-2 mM EDTA, pH 7-9) to obtain 10 μM. 1-50 μL of the above aptamer solution was annealed with a PCR instrument and added to the above M13-MB. The mixture was reacted at 20-40° C. in a shaker for 2-10 h. The product Apt-M13-MB was obtained by magnetic separation, which was the M13 phage magnetic material.

[0015] An M13 bacteriophage magnetic material is prepared by the above preparation method.

[0016] The present invention also provides an application of an M13 bacteriophage magnetic material as described below.

[0017] The invention discloses an application of the M13 bacteriophage magnetic material in capturing and releasing circulating tumor cells.

[0018] The M13 phage magnetic material can achieve efficient capture of circulating tumor cells in actual blood samples of breast cancer patients, and can distinguish different molecular subtypes of breast cancer. Therefore, it is used in the preparation of breast cancer samples to achieve the capture of cancer cells and the application of diagnostic compositions to distinguish different subtypes of breast cancer.

[0019] The application of the M13 phage magnetic material in capturing EpCAM-negative cells.

[0020] A method for capturing and releasing circulating tumor cells based on bacteriophage magnetic materials comprises the following steps:

[0021] Cell capture and release process: Count cells (suspended in PBS buffer solution) under a microscope using a hemocytometer. Dilute the cells to obtain a cell suspension, add Apt-M13-MB PBS buffer solution, mix evenly, and react in a shaker at 20-40°C for 10-80 minutes. Then, magnetic separation is performed on the product, the supernatant is collected and counted, and the cell capture efficiency is calculated using the following formula.

[0022]

[0023] The obtained Apt-M13-MB material and the captured cell mixture were resuspended in PBS buffer solution, DNaseI enzyme was added to make the final concentration 25-200U / mL, and the solution was evenly mixed and placed on a shaker for 15-75min at 25-40°C. The product was then magnetically separated, the supernatant was collected, and the cells released in the supernatant were counted, and the cell release efficiency was calculated by the formula.

[0024]

[0025] Activity and re-culture experiments of cells after capture and release: Incubate the cells with Apt-M13-MB material, and capture and release the cells according to the above steps. Stain the released cells with AO / PI and observe them under a fluorescence microscope, and calculate the cell activity using the following formula. Resuspend the released cells in a cell culture dish and observe the cell morphology after a period of time.

[0026]

[0027] The key technical point of the present invention is to prepare a magnetic material of M13 phage pVIII protein multivalent display aptamer, which can efficiently capture and release circulating tumor cells. 2700 pVIII protein copies provide enough reaction sites for hundreds of binding ligands, and the flexibility of M13 phage allows it to freely twist and adjust the ligand configuration, adaptively adapt to the distribution pattern of target receptors on the cell surface, thereby greatly enhancing its multivalent interaction with CTC. In addition, the swing of phage is more conducive to DNase I enzyme contact aptamer to increase the release of CTC. At the same time, M13 phage magnetic material can capture EpCAM negative expression cells in actual clinical breast cancer samples using MUC1 aptamers, and realize the distinction of different breast cancer subtypes by fluorescent antibody staining.

[0028] Beneficial effects of the present invention:

[0029] The present invention uses M13 bacteriophage as a scaffold, pIII protein gene displays histidine-linked magnetic spheres, and pVIII protein modifies MUC1 aptamers through click reaction to capture and release circulating tumor cells. Figure 2 , Figure 3As shown, the prepared M13 phage magnetic material (Apt-M13-MB) has a capture efficiency of 95.63% for MCF-7 cells in PBS, a release efficiency of 89.98% for MCF-7 cells in PBS, and a cell activity of 97.14%, which is beneficial for subsequent research on CTCs. Compared with the traditional method of direct modification with monovalent aptamers, the capture efficiency of this system in whole blood is increased by 46.4%, which is calculated as follows: the capture efficiency of Apt-M13-MB for 100 cells / mL of MCF-7 cells in whole blood is 91.19% minus the capture efficiency of Apt-MB for 100 cells / mL of MCF-7 cells in whole blood is 44.79%, which equals to 46.4%, and the release efficiency is increased by 35%, which is calculated as follows: the release efficiency of Apt-M13-MB for 100 cells / mL of MCF-7 cells in whole blood is 82.59% minus the capture efficiency of Apt-MB for 100 cells / mL of MCF-7 cells in whole blood is 47.99%, which equals to 34.60%. At the same time, M13 phage magnetic materials can also be used for the diagnosis of actual clinical breast cancer samples and for distinguishing different subtypes of breast cancer. They also have good capture performance for EpCAM-negative cells, greatly reducing the missed detection rate and false negative results of CTC. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Preparation process of Apt-M13-MB.

[0031] Figure 2 A is a comparison of the capture performance of Apt-M13-MB and Apt-MB systems for 100 cells / mL of different cells in whole blood and PBS buffer solution; B is the release performance of Apt-M13-MB and Apt-MB systems for 100 cells / mL of MCF-7 and A549 cells in whole blood and buffer solution.

[0032] Figure 3 A is a fluorescent image of cells captured and released by Apt-M13-MB material after being stained with AO / PI; B is the cell survival rate; C is the cells just released; D is a picture of cells cultured 36 hours after release.

[0033] Figure 4 A is the capture efficiency of Apt-M13-MB material for different breast cells in whole blood; B is the number of CTCs captured in the blood of actual clinical patients and healthy volunteers; C is the immunofluorescence staining image of white blood cells and CTCs separated from the blood samples of breast cancer patients. Scale bar: 20μm. DETAILED DESCRIPTION

[0034] A method for preparing an M13 bacteriophage magnetic material, such as Figure 1As shown, the steps are as follows:

[0035] Preparation of 6His-M13 phage: Two synthetic phosphorylated oligonucleotide chains 6H-PSA1 (5'-GTACCTTTCTATTCTCACTCTCATCATCATCATCATCATTCCTCCAAACTGCAGTC-3) and 6H-PSA2 (5'-GGCCGACTGCAGTTTGGAGGAATGATGATGATGATGATGAGAGTGAGAATAGAAAG-3) were annealed and hybridized at 95℃ for 5min to obtain the terminal double-stranded DNA 6H-PSA for ligation. The M13KE vector was digested with Acc65I and EagI and purified using a gel purification kit. 6H-PSA was ligated into the linearized M13KE with T4 ligase at 16℃ overnight. The ligation product was transformed into Escherichia coli TG1 strain (E. coli TG1) using the CaCl2 transformation method. Phage plaques were screened on LB agar plates containing IPTG and X-Gal and verified by DNA sequencing.

[0036] Synthesis of N3-M13: Take 10 μL with a titer of 6×10 13 pfu / mL of 6His-M13 phage was dissolved in 240 μL of 50 mM sterile PBS buffer solution (pH 7.8) and mixed, and 250 μL of 10 mM NHS-PEG-N3 solution was added, mixed evenly, and placed in a shaker at 4°C for 18 hours. The solution after the reaction was taken out, and the excess NHS-PEG-N3 reagent was removed using a 100 kDa ultrafiltration tube to obtain N3-M13, which was placed in a 4°C refrigerator for use.

[0037] Preparation of M13-MB: Take 2.5 mg / mL His-Tag protein purification magnetic beads (nickel ion) IDA-Nickel, wash three times with 10 mM PBST (pH 7.4, containing 3% BSA, 0.01% tween-20) buffer solution, and resuspend in PBST solution after magnetic separation. Add purified 1×10 10 The pfu N3-M13 solution was evenly mixed and placed in a mixer for reaction for 3 hours. The product after the reaction was magnetically separated, washed twice with PBST buffer and resuspended to obtain M13-MB, which was stored in a refrigerator at 4°C.

[0038] Apt-M13-MB: MUC1 aptamer (5'-TTTTTGCAGTTGATCCTTTGGATACCCTGG-3', DBCO modified) was diluted with TE buffer solution (10mM tris-HCl, 1mM EDTA, pH 8.0) to obtain 10μM. 25μL of the above aptamer solution was annealed with a PCR instrument. Annealing process: The parameters set for the PCR instrument were 95℃ for 6min, then directly dropped from 95℃ to 65℃, and kept at 65℃ for 1min, then from 65℃ to 25℃, dropping 1℃ per minute. Then, it was added to the above M13-MB and reacted at 25℃ in a shaker for 6h. The product Apt-M13-MB was obtained by magnetic separation, which is the M13 phage magnetic material.

[0039] A method for capturing and releasing circulating tumor cells based on the above-mentioned M13 bacteriophage magnetic material, the specific operation steps are as follows:

[0040] Capture, release and typing of CTCs in clinical samples: 500 μL of whole blood was incubated with Apt-M13-MB material and released according to the following steps.

[0041] The cells suspended in PBS buffer solution were counted under a microscope using a hemocytometer. The cells were diluted to obtain 500 μL of cell suspension, 500 μL of Apt-M13-MB PBS buffer solution was added, mixed evenly, and reacted in a shaker at 37°C for 30 min. The product was then magnetically separated, the supernatant was collected and counted, and the cell capture efficiency was calculated using the following formula.

[0042]

[0043] The obtained Apt-M13-MB material and the captured cell mixture were resuspended in PBS buffer solution, DNaseI enzyme was added to make the final concentration 100U / mL, and the solution was evenly mixed and placed on a shaker for 20 minutes at 37°C. The product was then magnetically separated, the supernatant was collected, and the cells released in the supernatant were counted, and the cell release efficiency was calculated by the formula.

[0044]

[0045] The released cells were fixed on a glass slide with 4% paraformaldehyde and blocked with blocking solution. The captured CTCs were then stained with antibodies using a nuclear staining solution DAPI, a leukocyte marker anti-CD45, and a keratin marker for CTCs CK and observed under a fluorescence microscope. When DAPI+ / ant-CD45+ / CK-, they were identified as leukocytes, and when DAPI+ / ant-CD45- / CK+, they were identified as CTCs.

[0046] To evaluate the feasibility of M13 bacteriophage magnetic materials in clinical breast cancer patients.

[0047] First, Apt-M13-MB material captured breast cells at four different concentrations spiked with whole blood. Figure 4 As shown in A, the capture efficiency of the three cell lines MCF-7, MDA-MB-231 and SK-BR-3, which are positive for MUC1 aptamer expression, is higher than 83.34%, while the capture efficiency of the normal breast epithelial cell line MCF-10A, which is negative for MUC1 aptamer, is less than 6.99%, indicating that the M13 phage magnetic material can selectively capture different subtypes of breast cancer cell lines. Then, blood samples from 18 breast cancer patients and 14 healthy volunteers / benign patients were analyzed to evaluate the diagnostic performance of Apt-M13-MB. Figure 4 As shown in Figure B, there are 4 to 47 CTCs per ml of blood in cancer patients, while no more than 5 CTCs are found in the blood of healthy blood donors or benign patients, indicating that this material can be well used for the diagnosis of cancer patients at different stages. Figure 4 As shown in C, the captured cells are distinguished by antibody fluorescent staining, and even EpCAM-negative cells can be captured.

Claims

1. A method for preparing an M13 bacteriophage magnetic material, characterized in that Proceed as follows: Preparation of 6His-M13 phage: two phosphorylated oligonucleotide chains 6H-PSA1 (5'-GTACCTTTCTATTCTCACTCTCATCATCATCATCATCATTCCTCCAAACTGCAGTC-3) and 6H-PSA2 (5'-GGCCGACTGCAGTTTGGAGGAATGATGATGATGATGATGAGAGTGAGAATAGAAAG-3) were annealed and hybridized at 90-100°C for 2-10 min to obtain the terminal double-stranded DNA 6H-PSA for ligation; the M13KE vector was digested with Acc65I and EagI and purified with a gel purification kit; 6H-PSA was ligated to the linearized M13KE at 4-20°C overnight with T4 ligase; the ligation product was transformed into chemically competent host cells using the CaCl2 transformation method; phage plaques were screened on LB agar plates containing IPTG and X-Gal and verified by DNA sequencing; Synthesis of N3-M13: Dissolve 6His-M13 phage in sterile PBS buffer solution and mix well, add NHS-PEG-N3 solution, mix evenly, and place in a shaker at a temperature of 0-37°C to react for 10-24 hours; take out the solution after the reaction, remove excess NHS-PEG-N3 reagent, obtain N3-M13, and place it in a refrigerator at 0-15°C for use; Preparation of M13-MB: Take the IDA-MBs storage solution, wash it three times with PBST buffer solution, and resuspend it in PBST solution after magnetic separation; add the purified N3-M13 solution, mix it evenly, and place it under a mixer to react for 30min to 12h; separate the product after the reaction magnetically, wash it twice with PBST buffer and resuspend it to obtain M13-MB, and place it in a refrigerator at 0 to 15°C for use; Apt-M13-MB: The MUC1 aptamer was diluted with TE buffer solution, annealed with a PCR instrument, and then added to the above-mentioned M13-MB. The reaction was carried out in a shaker at 20-40°C for 2-10 hours. The product Apt-M13-MB was obtained by magnetic separation, which was the M13 phage magnetic material.

2. The method for preparing a M13 bacteriophage magnetic material according to claim 1, characterized in that In the synthesis step of N3-M13, 1 to 100 μL of a 1×10 11 pfu / mL~8×10 13 pfu / mL of 6His-M13 phage was dissolved in 150-300 μL of 10-100 mM sterile pH 7-8 PBS buffer solution and mixed evenly, and 100-200 μL of 5-20 mM NHS-PEG-N3 solution was added and mixed evenly.

3. The method for preparing an M13 bacteriophage magnetic material according to claim 1, characterized in that In the preparation step of M13-MB, 1-5 mg / mL IDA-MBs storage solution was taken, washed three times with 5-20 mM PBST buffer solution, and resuspended in PBST solution after magnetic separation; purified 1×10 9 pfu~1×10 12 pfu N3-M13 solution; the PBST buffer solution has a pH of 6-8 and contains 0.05-5% BSA and 0.01-0.5% tween-20.

4. The method for preparing an M13 bacteriophage magnetic material according to claim 1, characterized in that In the preparation steps of M13-MB, the IDA-MBs storage solution refers to His-Tag protein purification nickel ion magnetic beads.

5. An M13 bacteriophage magnetic material, characterized in that Prepared by the preparation method according to any one of claims 1 to 4.

6. Use of the M13 phage magnetic material according to claim 5 in capturing and releasing circulating tumor cells.

7. Use of the M13 phage magnetic material according to claim 5 in preparing a diagnostic composition for capturing cancer cells and distinguishing different subtypes of breast cancer in breast cancer samples.

8. Use of the M13 phage magnetic material according to claim 5 in capturing EpCAM-negative cells.

9. A method for capturing and releasing circulating tumor cells based on bacteriophage magnetic materials, characterized in that The steps include: Cell capture and release process: Count cells under a microscope using a hemocytometer, dilute the cells to obtain a cell suspension, add a PBS buffer solution of M13 bacteriophage magnetic material, mix evenly, react in a shaker at 20-40°C for 10-80 minutes, then magnetically separate the product, collect and count the supernatant, and calculate the cell capture efficiency using the following formula; The mixture of M13 phage magnetic material and captured cells was resuspended in PBS buffer solution, DNase I enzyme was added to make the final concentration of 25-200 U / mL, and the solution was evenly mixed and placed on a shaker, reacted at 25-40°C for 15-75 minutes, and then the product was magnetically separated, the supernatant was collected and the released cells in the supernatant were counted, and the cell release efficiency was calculated by the formula; Activity and re-cultivation experiment of cells after capture and release: co-incubate the cells with M13 phage magnetic materials, capture and release the cells according to the above steps, perform AO / PI staining on the released cells and observe them under a fluorescence microscope, calculate the cell activity by the following formula, resuspend the released cells in a cell culture dish and culture them, and observe the cell morphology after a period of time;

Citation Information

Cited By

  • Preparation method and application of universal renewable immunoaffinity magnetic beads

    CN119916014A

  • Preparation method and application of a general updatable immune affinity magnetic bead

    CN119916014B